COPN.SW - Cosmo Pharmaceuticals N.V.

Swiss - Swiss Delayed Price. Currency in CHF

47.30

-0.65

(-1.36%)

At close: 05:31PM CEST

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	47.95
Open	48.00
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	47.10 - 48.00
52 Week Range	42.30 - 69.50
Volume	3,596
Avg. Volume	12,911

Market Cap	769.103M
Beta (5Y Monthly)	1.06
PE Ratio (TTM)	46.37
EPS (TTM)	1.02
Earnings Date	Jul 27, 2023
Forward Dividend & Yield	1.02 (2.17%)
Ex-Dividend Date	May 31, 2023
1y Target Est	80.83

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for COPN.SW

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Simply Wall St.
Cosmo Pharmaceuticals N.V. (VTX:COPN) Is About To Go Ex-Dividend, And It Pays A 2.0% Yield
Readers hoping to buy Cosmo Pharmaceuticals N.V. ( VTX:COPN ) for its dividend will need to make their move shortly, as...
Simply Wall St.
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
With its stock down 17% over the past three months, it is easy to disregard Cosmo Pharmaceuticals (VTX:COPN). However...
Simply Wall St.
Cosmo Pharmaceuticals (VTX:COPN) shareholders have endured a 58% loss from investing in the stock five years ago
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
Simply Wall St.
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/E Still Appears To Be Reasonable
With a price-to-earnings (or "P/E") ratio of 53.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...
Zacks
Medtronic (MDT) to Enhance AI Innovation With New Platform
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
Simply Wall St.
Private companies account for 46% of Cosmo Pharmaceuticals N.V.'s (VTX:COPN) ownership, while individual investors account for 36%
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
Simply Wall St.
Is Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that Cosmo Pharmaceuticals' (VTX:COPN) stock increased significantly by 20% over...
Simply Wall St.
Cosmo Pharmaceuticals (VTX:COPN) adds €69m to market cap in the past 7 days, though investors from five years ago are still down 60%
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders should be happy to see the share price up 20% in the last month...